Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis

References

• Ciprandi G, Buscaglia S, Cerqueti PM, Canonica GW. Drug treatment of allergic conjunctivitis – a review of the evidence. Drugs 1992;43:154–76
   PubMed Web of Science ®Google Scholar
• Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease subtypes, and treatment. The Ocular Surface 2003;1(3):127
   Google Scholar
• Sharif NA, Xu SX, Miller ST, Gamache DA, Yanni JM. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278: 1252–61
   Google Scholar
• Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther 1996;12:389–400
   PubMed Web of Science ®Google Scholar
• Yanni JM, Weimer LK, Sharif NA, Xu SX, Gamache DA, Spellman JM. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643–7
   PubMed Web of Science ®Google Scholar
• Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Immunol 1997;79:541–5
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278:1252–61
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits TNFa release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000;84:1–5
   PubMedGoogle Scholar
• Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocular Pharmacol Ther 1996;12:389–400
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Yanni JM. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocular Pharmacol Ther 1996;12: 401–7
   Google Scholar
• Sasaki Y, Ishii H, Ikemura T, et al. The antihistaminic effect of KW-4679, a novel antiallergic drug. Clin Pharm Ther 1995;5:1825–35
   Google Scholar
• Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmaco-kinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002;88:379–97
   PubMedGoogle Scholar
• Yanni JM, Weimer LK, Sharif NA, et al. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs. Arch Ophthalmol 1999;117:643–7
   PubMed Web of Science ®Google Scholar
• Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003;25(10): 2539–52
   PubMed Web of Science ®Google Scholar
• Cook EB, Stahl JL, Barney NP, et al. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001;87:424–9
   PubMed Web of Science ®Google Scholar
• Ikemura T, Manabe H, Sasaki Y, et al. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int Arch Allergy Immunol 1996;110:57–63
   PubMed Web of Science ®Google Scholar
• Miyake K, Ohmori K, Ishii A, et al. Inhibitory effect of olopatadine hydrochloride (KW-4679), a novel antiallergic drug, on peptide leukotriene release from human eosinophils. Allergology Int 2001;50:113–6
   Google Scholar
• Fukuishi N, Matsuhisa M, Shimono T, et al. Inhibitory effect of olopatadine on antigen-induced eosinophil infiltration and the LFA-1 and Mac-1 expression in eosinophils. Jpn J Pharmacol 2002;88:463–6
   PubMedGoogle Scholar
• Abelson MB, Gomes PJ, Welch DL, et al. Olopatadine reduces ocular signs and symptoms associated with allergic conjunctivitis 16 hours after instillation. Presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2003 May 4; Fort Lauderdale, FL
   Google Scholar
• Greiner JV, Spindel GP, Gomes PJ, et al. Olopatadine is effective for the prevention and treatment of the signs and symptoms of allergic conjunctivitis. Presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2003 May 4; Fort Lauderdale, FL
   Google Scholar
• Vogelson CT, Abelson MB, Pasquine TA, et al. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. Allergy Asthma Proc 2004;25(1):69–75
   Google Scholar
• Lichtenstein SJ, Vogelson CT, Wells DT, et al. Olopatadine is safe and well-tolerated in adults and children as young as three-years of age. Presentation at the Annual Meeting of the Western Society of Allergy, Asthma, and Immunology (WSAAI); 2003 January 18; Maui, HI
   Google Scholar
• Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther 2004;26(8):1237–48
   Google Scholar
• Vogelson CT, Abelson MB, Gomes PJ, et al. Olopatadine 0.2% ophthalmic solution reduces some nasal symptoms in an environmental study of subjects with allergic conjunctivitis or rhinoconjunctivitis. Presentation and the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI); 2004 November 13; Boston, MA
   Google Scholar
• Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84–8
   Google Scholar
• Spitalny L, Abelson MB. Olopatadine ophthalmic solution decreases itching and redness associated with allergic conjunctivitis [abstract]. Invest Ophthal Vis Sci 1996;37(Suppl):2730
   Google Scholar
• Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998;125:797–804
   PubMed Web of Science ®Google Scholar
• Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81(3):211–18
   PubMed Web of Science ®Google Scholar
• Lanier B, Berger W, Turner FD, Drake M, Wall GM, Dimas C. Olopatadine 0.1% reduces frequency of seasonal allergic rhinitis (SAR) symptoms in patients exposed to high pollen levels. Presentation at the Western Society of Allergy, Asthma, and Immunology (WSAAI); 2004 January 27–30; Hawaii
   Google Scholar
• Gomes PJ, Krokhmal L, Abelson MB, Welch DL. Allergic rhino-conjunctivitis is mediated primarily through ocular exposure to allergen. Presentation at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO); 2004 April 29; Fort Lauderdale, FL
   Google Scholar
• Lanier BQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther 2002;24(7):1161–4
   PubMed Web of Science ®Google Scholar